Lead Product(s) : OC134
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Nanomerics
Deal Size : Inapplicable
Deal Type : Inapplicable
Quotient Sciences and Nanomerics Dose First Volunteers in the OC134 SUNLIGHT Trial
Details : OC134 is an eye drop medicine candidate indicated for the topical treatment of moderate to severe allergic conjunctivitis, a condition for which a suitable non-steroidal topical ocular treatment.
Product Name : OC134
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : OC134
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Nanomerics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atovaquone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Fresenius Kabi AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Quotient Doses Volunteers in Malaria Venture’s Long-Acting Injectable Prevention Study
Details : MMV371 is a prodrug of atovaquone (selective inhibitor of cytochrome bc1 complex), ben investigated for malaria in adults.
Product Name : MMV371-Prodrug
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2024
Lead Product(s) : Atovaquone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Fresenius Kabi AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxycodone Prodrug,Nafamostat Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Ensysce Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Ensysce Advances Overdose Protection Platform in Clinical Development
Details : The collaboration aims to examine and evaluate the full commercial dose range of the PF614-MPAR drug product, the combination of PF614 with the trypsin inhibitor nafamostat, to treat chronic pain.
Product Name : PF614-MPAR
Product Type : Controlled Substance
Upfront Cash : Undisclosed
May 20, 2024
Lead Product(s) : Oxycodone Prodrug,Nafamostat Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Ensysce Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : YCT529
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
UK Launches First Trial of Hormone-Free Male Birth Control Pill
Details : YCT-529 is a retinoic acid receptor-alpha (RAR-alpha) inhibitor that prevents sperm production by blocking access to vitamin A. It is under phase 1 clinical development for male contraception.
Product Name : YCT529
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2023
Lead Product(s) : YCT529
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atumelnant
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Crinetics Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Quotient will support Crinetics' CRN04894 pediatric program. The partnership will utilize Quotient Sciences' unique Translational Pharmaceutics® platform to provide integrated formulation development, clinical manufacturing, and t...
Product Name : CRN04894
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Atumelnant
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Crinetics Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Oxycodone Prodrug,Nafamostat
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Ensysce Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Ensysce Biosciences' PF614-MPAR Enters Final Stage of Phase 1 Study
Details : PF614-MPAR (oxycodone prodrug) binds and inhibits adenylyl-cyclase and hyperpolarisation of neurons, and decreased excitability, thus reduces severe pain. It is the first opioid drug product that has both abuse deterrent properties as well as overdose pr...
Product Name : PF614-MPAR
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 25, 2023
Lead Product(s) : Oxycodone Prodrug,Nafamostat
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Ensysce Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : HighTide Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : HTD1801 (berberine ursodeoxycholate), is a first-in-class new molecular entity, currently in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).
Product Name : HTD1801
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 15, 2022
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : HighTide Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Emplicure
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Quotient Sciences will support the GMP manufacture and first clinical pharmacokinetic (PK) study for EMPLI03 (buprenorphine) using its unique Translational Pharmaceutics® platform for the treatment of moderate to severe pain.
Product Name : Empli03
Product Type : Controlled Substance
Upfront Cash : Undisclosed
November 29, 2022
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Emplicure
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Aprepitant
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Oxilio
Deal Size : Undisclosed
Deal Type : Agreement
Details : Quotient has prior experience of working with the Nuformix NXP-001 co-crystal and previously developed a capsule and a powder for oral suspension formulation of Aprepitant, evaluating its performance in a relative bioavailability study versus EMEND.
Product Name : NXP-001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 02, 2022
Lead Product(s) : Aprepitant
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Oxilio
Deal Size : Undisclosed
Deal Type : Agreement
Oxilio Announces Start of Its First Clinical Trial With OXL001
Details : OXL001, has been developed utilising a novel bio-enabling platform technology, it has been taken into clinical studies which gives its immense potential as a pan-cancer therapy.
Product Name : OXL001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 11, 2022
KEY SERVICES
Reset All
Quotient Sciences- Molecule to Cure. Fast.
